UPCC 13424 Phenotypic and Endotypic Characterization of Infusion Reactions Related to Anti-CD20 and Anti-CD19 Monoclonal and Bispecific T Cell-Engaging Antibodies

Enrolling By Invitation
99 years or below
All
Phase N/A
120 participants needed
1 Location

Brief description of study

The objective is to obtain clinical (phenotypic) and laboratory (biomarker) data during immediate drug hypersensitivity reactions in L-RAD patients receiving anti-CD19 or anti-CD20 bispecific antibodies or monoclonal antibodies to classify them as a(an): (1) type 1 immediate hypersensitivity reaction (allergic) (2) cytokine release syndrome (CRS)
(3) infusion-related reaction (IRR)
(4) mixed reaction (MR).

Eligibility of study

You may be eligible for this study if you meet the following criteria:

  • Conditions: Medical Research
  • Age: 99 years or below
  • Gender: All

TBD

Updated on 22 Apr 2026. Study ID: 24-0273
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu For Cancer trials contact Penn Medicine's Cancer Trial Navigator at: PMCancerResearch@pennmedicine.upenn.edu or 215-349-8245

Study is selecting its participants from a population, or group of people, decided on by the researchers in advance.

Contact Abramson Cancer Center Navigator